Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Brenda G. Clark, PhD, Robert J

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006 Mark.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Frank Detterbeck, MD Journal of Thoracic Oncology

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Pulmonary Metastasectomy: A Survey of Current Practice Amongst Members of the European Society of Thoracic Surgeons Eveline Internullo, MD, Stephen D.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer Nami.

An Editorial Note: The Long Arm of Practical Radiation Oncology

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Self-Reported Cardiovascular Disease and the Risk of Lung Cancer, the HUNT Study Peter Hatlen, PhD, MD, Arnulf Langhammer, MD, PhD, Sven Magnus Carlsen,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions Samuel G. Armato, PhD, Anna K. Nowak, MD, PhD,

Mitotic Inhibitors Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Nicholas Trakul, MD, PhD, Jeremy P

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative.

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Combined Analysis of V20, VS5, Pulmonary Fibrosis Score on Baseline Computed Tomography, and Patient Age Improves Prediction of Severe Radiation Pneumonitis.

European Lung Cancer Conference (ELCC) 2016 Organisation

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

IASLC 6th Latin American Conference on Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative Radiotherapy Jayaji M. Moré, MS, Neville C.W. Eclov, BS, Melody P. Chung, BS, Jacob F. Wynne, BS, Joanne H. Shorter, PhD, David D. Nelson, PhD, Alexandra L. Hanlon, PhD, Robert Burmeister, PhD, Peter Banos, MD, Peter G. Maxim, PhD, Billy W. Loo, MD, PhD, Maximilian Diehn, MD, PhD Journal of Thoracic Oncology Volume 9, Issue 7, Pages 957-964 (July 2014) DOI: 10.1097/JTO.0000000000000182 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Sample NO and CO expiration profiles before and after SABR for patients that did and did not develop radiation pneumonitis (RP). Before SABR measurement shown in blue and after SABR measurement shown in red. Final concentrations were calculated as mean over the final 3 seconds of expiration, using American Thoracic Society/ European Respiratory Society recommendations for standardized measurement of exhaled NO. (A) NO expiration profile in patient who developed RP. (B) CO expiration profile in patient who developed RP. (C) NO expiration profile in patient who did not develop RP. (D) CO expiration profile in patient who did not develop RP. Journal of Thoracic Oncology 2014 9, 957-964DOI: (10.1097/JTO.0000000000000182) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Dot plots of baseline exhaled NO and CO concentrations for patients that did and did not develop RP. Bars show average values. A, Baseline exhaled NO concentrations. (B) Baseline exhaled CO concentrations. Current nonsmokers shown as filled circles and current smokers shown as open circles. Journal of Thoracic Oncology 2014 9, 957-964DOI: (10.1097/JTO.0000000000000182) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Dot plots of average acute percent changes in exhaled NO and CO after SABR for patients that did and did not develop RP. Bars show average values. The independent samples t test was used to assess significance. A, average acute change in exhaled NO after SABR. (B) Average acute change in exhaled CO after SABR. Journal of Thoracic Oncology 2014 9, 957-964DOI: (10.1097/JTO.0000000000000182) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions